Schrödinger, Inc.

Schrödinger, Inc.

SDGR
Schrödinger, Inc.US flagNASDAQ
20.09
USD
-0.62
- -
1.50BMarket Cap
Schrödinger, Inc.
SDGR
(NASDAQ)

Recent

price

20.09

P/E

ratio

- -

div

yld

- -

ROIC.AI

2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
1.38
1.37
1.44
1.8
1.95
2.54
3.02
2.86
3.48
3.5
Revenue per Share
-0.43
-0.59
-0.41
-0.41
-1.42
-2.1
0.57
-2.57
-1.41
-0.73
Basic EPS, GAAP
-0.47
-0.6
-0.47
0.24
-1.1
-1.79
-2.09
-2.27
0.17
-1.76
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-0.76
-1.2
-1.57
8.93
7.85
6.28
7.6
5.78
4.94
4.4
Book Value per Share
-0.76
-1.2
-1.57
8.93
7.85
6.2
7.54
5.72
4.88
4.33
Tangible Book Value per Share
40
48
60
60
71
71
72
73
73
74
Basic Weighted Avg Shares
56
67
86
108
138
181
217
208
256
259
Sales/Revenue/Turnover
-34.15
-41.97
-45.26
-56.35
-80.8
-81.13
-81.9
-100.85
-65.23
-59.24
Operating Margin (%)
2
3
4
4
3
4
6
6
6
6
Depreciation Expense
-17
-28
-25
-24
-100
-149
41
-187
-103
-54
Net Income, GAAP
- -
- -
- -
- -
- -
- -
5.12
- -
- -
20.08
Effective Tax Rate (%)
-31.23
-42.66
-28.72
-22.63
-72.78
-82.44
18.79
-90.16
-40.36
-20.98
Profit Margin (%)
30
78
74
610
534
425
434
443
330
297
Working Capital
- -
- -
9
7
78
105
111
101
93
92
LT Debt
-45
-72
-93
624
557
448
549
421
364
329
Total Equity
- -
- -
- -
- -
- -
- -
-27.14
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
-17
-29.69
8.17
-38.58
-26.29
-16.18
Return on Common Equity (%)

Capital Structure

FRC

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
16
16
16
LT Borrowings
- -
- -
- -
LT Finance Leases
93
91
92
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
74
75
75
Market Capitalization
1,317
847
1,215

Working Capital

FRC

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
519
464
470
Cash, Cash Equivalents & STI
395
399
414
Accounts Receivable, Net
83
27
21
Inventories
- -
- -
- -
Total Current Liabilities
189
170
174
Payables & Accruals
60
50
53
ST Debt
16
16
16
Deferred Revenue
113
103
105

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-8.93%
-13.62%
Free Cash Flow
- -
-132.73%
-107.56%
Net Income, GAAP
- -
-74.53%
-44.81%
Sales/Revenue/Turnover
- -
19.52%
23.29%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
37
47
35
88
208
2025
60
55
54
87
256
2026
59
59
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.76
-0.74
-0.52
- -
-2.57
2025
-0.82
-0.59
-0.45
- -
-1.41
2026
-0.81
0.08
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Business
Schrödinger, Inc. (SDGR) develops physics-based computational platforms that accelerate the discovery of novel molecules for drug development and materials applications. The company offers a comprehensive suite of software products and services, including its flagship Schrödinger Platform comprising physics-based simulation software such as LiveDesign for collaborative design, Desmond and FEP+ for molecular dynamics and free energy perturbation calculations; Maestro for molecular visualization and modeling; and the Materials Science Suite for property prediction and optimization; alongside cloud-based services like Schrödinger Cloud for scalable computations, consulting services for custom model development, and enterprise solutions integrating AI-driven predictions with proprietary datasets. Founded in 1990 and headquartered in New York, the company primarily serves the biopharmaceutical, biotechnology, and chemical industries, with customers spanning North America, Europe, and Asia-Pacific regions, including major players like Pfizer, Takeda, and Novartis. In recent developments within the last two years, Schrödinger expanded its offerings through strategic collaborations, such as enhanced partnerships with biotech firms for AI-hybrid drug discovery pipelines, and continued investment in machine learning integrations to its platform amid growing demand for computational efficiency in R&D.

Company News

  • Schrödinger to Present at Morgan Stanley Global Healthcare Conference

  • BlackRock Inc. Buys New Shares in Schrodinger, Inc. $SDGR

  • 4 AI-Powered Drug Discovery Stocks to Watch as AI Reshapes Pharma

  • Schrodinger Inc (SDGR) Stock Down 4.8% -- Now Undervalued? GF Score: 73/100

  • Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

  • Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

  • Critical Review: Schrodinger (NASDAQ:SDGR) versus Weave Communications (NYSE:WEAV)

  • The Biggest IPO of the Year Is Targeted in the Next 60 Days. Why One Unexpected Industry Could Rally Before Then (Hint: It’s Not Tech)

  • Schrödinger, Inc. (SDGR) Q2 2026 Earnings Call Transcript

  • Schrodinger Q2 Earnings Call Highlights

  • Schrodinger Q2 Earnings Call Highlights

  • Schrodinger, Inc. (SDGR) Q2 Earnings and Revenues Top Estimates

  • Schrödinger Reports Second Quarter 2026 Financial Results

  • Schrödinger Announces Strategic Collaboration and Software Agreement with Bristol Myers Squibb to Deploy AI Co-Scientist Bunsen for Agentic Drug Discovery

  • Schrodinger: A Rare AI-Adjacent Disruptor Still Not Priced For It

  • Schrödinger Introduces Bunsen, an AI Co-Scientist for Molecular Discovery

  • An AI Biotech Just Reported a 46% Revenue Jump and Its First Recurring Platform Contracts, as Its Pivot Starts Showing Up in the Numbers

  • Schrödinger to Announce Second Quarter 2026 Financial Results on August 5

  • Schrodinger, Inc. $SDGR Shares Purchased by Amova Asset Management Americas Inc.

  • Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)